Novel, non-opioid, non-addictive intrathecal therapy for the treatment of chronic pain

Active Cooperative Agreement Awarded Last action

Award ID
UH3NS123965
Recipient
Awarding agency
Obligated
$29,234,629

Award facts

Assistance listing
93.279 Drug Use and Addiction Research Programs
Completion date 95% complete
Originally
Place of performance
Massachusetts, USA

Award details come from USAspending.gov.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $0
Amendment $353,950
Amendment $353,950
Amendment $353,950
Amendment $353,950
Amendment $3,185,557
Amendment $3,185,557
Amendment $3,185,557
Amendment $3,185,557
Amendment $3,185,557
Amendment $400,000
Amendment $400,000
Amendment $400,000
Amendment $2,672,761
Amendment $2,672,761
Amendment $2,672,761
Original award $2,672,761
Show all 22

Quick answers

Who received award UH3NS123965?

UH3NS123965 was awarded to Centrexion Therapeutics Corp by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on September 30, 2021.

How much is award UH3NS123965 worth?

$29,234,629 has been obligated on UH3NS123965.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award